Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Gertig, Dorota M ^a,b   Brotherton, Julia M L ^a,b   Budd, Alison C ^c   Drennan, Kelly ^a   Chappell, Genevieve ^a   Saville, A Marion ^a  

^a VCS Inc   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; REGISTER; SCREENING; SOCIAL STATUS; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VACCINATION; WART VIRUS;

ADOLESCENT; CHILD; COHORT STUDIES; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VACCINATION; VICTORIA;

EID: 84886935298     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-227     Document Type: Article

References (34)

1. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2010, 128:927-935.
2. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632. 10.1002/ijc.22527, 17405118.
3. The Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med 2007, 356:1915-1927. The Future II Study Group.
4. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. 10.1016/S0140-6736(09)61248-4, 19586656, HPV PATRICIA Study Group.
5. Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, Kjaer SK. HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol 2012, 124:281-285. 10.1016/j.ygyno.2011.10.020, 22036987.
6. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 2010, 19:1675-1681. 10.1158/1055-9965.EPI-10-0251, 2901898, 20615885.
7. Brotherton JM, Tabrizi SN, Garland SM. Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. Future Microbiol 2012, 7:193-199. 10.2217/fmb.11.161, 22324989.
8. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1157-1164. 10.1158/1055-9965.EPI-04-0812, 15894666.
9. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM. Human papillomavirus vaccine introduction - the first five years. Vaccine 2012, 30:F139-F148.
10. Victorian Cervical Cytology Registry Statistical Report 2011. VCCR Update on Cervical Screening in Victoria. [http://www/vccr.org.au/stats.html], Victorian Cervical Cytology Registry.
11. Brotherton J, Gertig D, Chappell G, Rowlands L, Saville M. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 year from the National HPV Vaccination Program Register. Commun Dis Intell Q Rep 2011, 35:197-201.
12. Australian Institute of Health and Welfare Cervical Screening in Australia 2009-2010 Canberra: Australian Institute of Health and Welfare: Australian Institute of Health and Welfare Cat. no.: CAN63, Cancer Series Number 67, [http://www.aihw.gov.au/publication-detail/?id=10737421580], Australian Institute of Health and Welfare.
13. Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011, 8:171-178. 10.1071/SH10001, 21592430.
14. Brotherton J. The first cab off the rank: the early Australian experience of universally funded HPV vaccine for women aged 12-26 years. HPV Today 2009, Number 17. [http://www.g-o-c.org/uploads/hpvtoday_mar_2009.pdf].
15. Chief Medical Officer Guidance on revaccination where HPV vaccine doses have been given at less than recommended minimum intervals. 2009, [http://www.health.gov.au/internet/immunise/publishing.nsf/Content/cmo-full-advice-hpv-cnt/$File/CMO-full-advice-hpv.pdf], Chief Medical Officer.
16. The NHMRC Screening to Prevent Cervical Cancer: Guidelines for the Management of Asymptomatic Women with Screen Detected Abnormalities. [http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/content/guide].
17. ABS Information Paper: an introduction to Socio-Economic Indexes for Areas (SEIFA) 2006 2008, Canberra: ABS, http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/2039.0Main+Features12006?OpenDocument, ABS.
18. SAS® Enterprise Guide® [http://www.sas.com/technologies/bi/query_reporting/guide/].
19. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30:F123-F138.
20. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, HPV PATRICIA Study Group Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99. Erratum in: Lancet Oncol 2012, 13:e1, 10.1016/S1470-2045(11)70286-8, 22075171, HPV PATRICIA Study Group.
21. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA Study Group Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170. Erratum in: Lancet 2007, 370:1414, 10.1016/S0140-6736(07)60946-5, 17602732, HPV PATRICIA Study Group.
22. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102:325-339. 10.1093/jnci/djp534, 20139221.
23. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131:2349-2359. 10.1002/ijc.27485, 22323075.
24. Bohensky MA, Jolley D, Sundararajan V, Evans S, Ibrahim J, Brand C. Development and validation of reporting guidelines for studies involving data linkage. Aust NZ J Public Health 2011, 35:486-489.
25. Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R, CVT Vaccine Group Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011, 12:862-870. Erratum in: Lancet Oncol 2011, 12:1096, 10.1016/S1470-2045(11)70213-3, 3172992, 21865087, CVT Vaccine Group.
26. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309:1793-1802. 10.1001/jama.2013.1625, 23632723.
27. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, et al. GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985. GlaxoSmithKline Vaccine HPV-007 Study Group.
28. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206:1645-1651. 10.1093/infdis/jis590, 23087430.
29. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032. Erratum in: BMJ 2013, 346:F2942, 10.1136/bmj.f2032, 23599298.
30. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012, 102:833-835. 10.2105/AJPH.2011.300465, 22420808.
31. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011, 124:51-58.
32. Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, Simard JF. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012, 206:860-866. 10.1093/infdis/jis405, 22815381.
33. Sexually transmitted infections in New Zealand. 2011 Surveillance Report [http://www.surv.esr.cri.nz/PDF_surveillance/STISurvRpt/2011/2011AnnualSTIRpt.pdf].
34. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092. 10.1016/S0140-6736(11)60551-5, 21684381.